source
- Pfizer halts phase 2 trial of CXCR5 antibody for immune thrombocytopeniaPfizer announced it is ending a phase 2 study of its CXCR5-targeting antibody PF-06835375 in patients with primary immune thrombocytopenia (ITP). The decision was described as a business decision a…
- FDA issues import alert on Olympus endoscopic devices over quality violationsThe U.S. Food and Drug Administration has issued an import alert for certain medical devices manufactured in Japan by Olympus Medical Systems Corporation and its subsidiaries. The alert applies to…